89189-34-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Ethyl-5-nitrophenylsulfonyl chloride is used as a starting material for the synthesis of various pharmaceuticals, leveraging its reactivity as a potent electrophile to form sulfonamide derivatives, which are important in the development of new drugs.
Used in Agrochemical Industry:
ENPS chloride serves as a starting material in the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals that enhance crop protection and yield.
Used in Dye and Pigment Production:
2-Ethyl-5-nitrophenylsulfonyl chloride is utilized as a chemical intermediate in the production of dyes and pigments, playing a crucial role in creating a wide range of colors for various applications, including textiles, plastics, and printing inks.
Used in Specialty Chemicals Industry:
ENPS chloride is employed in the synthesis of specialty chemicals, where its unique properties and reactivity contribute to the development of high-value products for specific applications in industries such as coatings, adhesives, and advanced materials.

Upstream product

• 100-12-9 4-ethylnitrobenzene 

Downstream Products

• 89189-33-3 4-ethyl-3-mercaptoaniline 
• 91559-02-3 4-(2-ethyl-5-nitro-benzenesulfonyl)-morpholine 
• 58443-49-5 C₈H₉NO₅S 
• 1101118-50-6 N'-((5-cyanopyrazolo[1,5-a]pyridin-3-yl)methylene)-2-ethyl-N-methyl-5-nitrobenzenesulfonohydrazide 
• 5339-33-3 6-aminobenzothiophene 

Relevant academic research and scientific papers

A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification

The bromodomain of ATAD2 has proved to be one of the least-tractable proteins within this target class. Here, we describe the discovery of a new class of inhibitors by high-throughput screening and show how the difficulties encountered in establishing a screening triage capable of finding progressible hits were overcome by data-driven optimization. Despite the prevalence of nonspecific hits and an exceptionally low progressible hit rate (0.001%), our optimized hit qualification strategy employing orthogonal biophysical methods enabled us to identify a single active series. The compounds have a novel ATAD2 binding mode with noncanonical features including the displacement of all conserved water molecules within the active site and a halogen-bonding interaction. In addition to reporting this new series and preliminary structure-activity relationship, we demonstrate the value of diversity screening to complement the knowledge-based approach used in our previous ATAD2 work. We also exemplify tactics that can increase the chance of success when seeking new chemical starting points for novel and less-tractable targets.

BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF

The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis

Abstract The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel present in the membrane of epithelial cells. Mutations affecting the CFTR gene cause cystic fibrosis (CF), a multi-organ severe disease. The most common CF mutation, F508del, impairs the processing and activity (gating) of CFTR protein. Other mutations, like G551D, only cause a gating defect. Processing and gating defects can be targeted by small molecules called generically correctors and potentiators, respectively. Aminoarylthiazoles (AATs) represent an interesting class of compounds that includes molecules with dual activity, as correctors and potentiators. With the aim to improve the activity profile of AATs, we have now designed and synthesized a library of novel compounds in order to establish an initial SAR that may provide indications about the chemical groups that are beneficial or detrimental for rescue activity. The new compounds were tested as correctors and potentiators in CFBE41o-expressing F508del-CFTR using a functional assay. A dual active compound, AAT-4a, characterized by improved efficacy and marked synergy when combined with the corrector VX-809 has been identified. Moreover, by computational methods, a possible binding site for AATs in nucleotide binding domain NBD1 has been detected. These results will direct the synthesis of new analogues with possibly improved activity.

Intramolecular C-H amination with sulfonyl azides

Cobalt (II) complexes of porphyrins are effective catalysts for intramolecular nitrene insertion of C—H bonds with arylsulfonyl azides. The cobalt-catalyzed process can proceed efficiently under mild and neutral conditions in low catalyst loading without

Cobalt-catalyzed intramolecular C-H amination with arylsulfonyl azides

(Chemical Equation Presented) Cobalt complexes of porphyrins are effective catalysts for intramolecular C-H amination with arylsulfonyl azides. The cobalt-catalyzed process can proceed efficiently under mild and neutral conditions in low catalyst loading